Abbott Laboratories (ABT) Holdings Held by DE Burlo Group Inc.

DE Burlo Group Inc. continued to hold its stake in shares of Abbott Laboratories (NYSE:ABT) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,800 shares of the healthcare product maker’s stock at the end of the 2nd quarter. DE Burlo Group Inc.’s holdings in Abbott Laboratories were worth $233,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in ABT. Winfield Associates Inc. increased its holdings in Abbott Laboratories by 3.9% in the second quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock valued at $116,000 after buying an additional 89 shares during the last quarter. V Wealth Management LLC acquired a new position in Abbott Laboratories in the second quarter valued at approximately $127,000. JFS Wealth Advisors LLC boosted its stake in Abbott Laboratories by 349.0% in the second quarter. JFS Wealth Advisors LLC now owns 2,694 shares of the healthcare product maker’s stock valued at $131,000 after acquiring an additional 2,094 shares during the period. Atwood & Palmer Inc. boosted its stake in Abbott Laboratories by 157.5% in the first quarter. Atwood & Palmer Inc. now owns 3,270 shares of the healthcare product maker’s stock valued at $145,000 after acquiring an additional 2,000 shares during the period. Finally, Farmers National Bank boosted its stake in Abbott Laboratories by 1.5% in the first quarter. Farmers National Bank now owns 3,568 shares of the healthcare product maker’s stock valued at $158,000 after acquiring an additional 52 shares during the period. 71.35% of the stock is owned by hedge funds and other institutional investors.

ABT has been the subject of a number of research reports. Zacks Investment Research downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. J P Morgan Chase & Co initiated coverage on Abbott Laboratories in a research note on Friday, October 6th. They issued a “neutral” rating and a $60.00 target price for the company. Royal Bank Of Canada restated a “buy” rating and issued a $55.00 target price on shares of Abbott Laboratories in a research note on Tuesday, October 3rd. Cowen and Company set a $68.00 target price on Abbott Laboratories and gave the company a “buy” rating in a research note on Thursday, October 19th. Finally, Barclays PLC restated an “overweight” rating and issued a $57.00 target price (up from $52.00) on shares of Abbott Laboratories in a research note on Saturday, July 22nd. Seven analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Abbott Laboratories has an average rating of “Buy” and a consensus price target of $56.81.

In other news, insider Jaime Contreras sold 52,700 shares of the stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $51.97, for a total transaction of $2,738,819.00. Following the sale, the insider now directly owns 58,739 shares of the company’s stock, valued at $3,052,665.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Stephen R. Fussell sold 196,550 shares of the stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $49.50, for a total transaction of $9,729,225.00. Following the sale, the insider now directly owns 221,488 shares in the company, valued at $10,963,656. The disclosure for this sale can be found here. Insiders have sold 408,313 shares of company stock worth $21,205,356 over the last three months. 0.76% of the stock is owned by insiders.

Abbott Laboratories (NYSE:ABT) opened at 54.23 on Wednesday. The stock’s 50 day moving average price is $53.92 and its 200 day moving average price is $49.13. The firm has a market capitalization of $94.22 billion, a P/E ratio of 75.95 and a beta of 1.06. Abbott Laboratories has a 12 month low of $37.38 and a 12 month high of $56.69.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.01. Abbott Laboratories had a net margin of 8.37% and a return on equity of 14.50%. The business had revenue of $6.83 billion for the quarter, compared to analysts’ expectations of $6.72 billion. During the same period in the prior year, the firm earned $0.59 earnings per share. Abbott Laboratories’s revenue was up 28.8% compared to the same quarter last year. On average, analysts forecast that Abbott Laboratories will post $2.50 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be paid a dividend of $0.265 per share. The ex-dividend date of this dividend is Thursday, October 12th. This represents a $1.06 annualized dividend and a dividend yield of 1.95%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 83.47%.

WARNING: This article was originally published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.com-unik.info/2017/11/01/abbott-laboratories-abt-holdings-held-by-de-burlo-group-inc.html.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

What are top analysts saying about Abbott Laboratories? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Abbott Laboratories and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit